<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783846</url>
  </required_header>
  <id_info>
    <org_study_id>MHX00123</org_study_id>
    <nct_id>NCT02783846</nct_id>
  </id_info>
  <brief_title>The Effects of Different Doses of Dexmedetomidine on Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index: a Double-blinded, Placebo-controlled Trial</brief_title>
  <official_title>The Effects of Different Dexmedetomidine on the Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of different dexmedetomidine on the
      propofol requirement for loss of consciousness undergoing bispectral index.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown that dexmedetomidine was an efficacious and safe adjuvant in general
      anaesthesia. Administration of dexmedetomidine during the preoperative period has been
      demonstrated to reduce the requirement of opioid analgesics and other sedative and hypnotic
      drugs.Therefore, the study is designed to measure the effect of intravenous dexmedetomidine
      premedication on the propofol dose requirement and bispectral index at loss of consciousness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The propofol requirement for pretreatment of dexmedetomidine by micro-pump until loss of consciousness</measure>
    <time_frame>To infuse dexmedetomidine and saline completely ten minutes after</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The bispectral index values when patients loss of consciousness</measure>
    <time_frame>To infuse dexmedetomidine and saline completely ten minutes after</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Loss of Consciousness</condition>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 eligible patients are received equal volumes of saline intravenously for 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group dexmedetomidine 0.5 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group dexmedetomidine 1.0 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>receive equal volume of normal saline</description>
    <arm_group_label>Group control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 0.5 µg/kg</intervention_name>
    <description>receive dexmedetomidine 0.5 µg/kg</description>
    <arm_group_label>Group dexmedetomidine 0.5 µg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 1.0 µg/kg</intervention_name>
    <description>receive dexmedetomidine 1.0 µg/kg</description>
    <arm_group_label>Group dexmedetomidine 1.0 µg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I-II

          -  Aged 18-65 years

          -  Body Mass Index 18.0～24.5 kg/m2

          -  Without hearing impairment

        Exclusion Criteria:

          -  Bradycardia

          -  Atrioventricular block

          -  Neurologic disorder and recent use of psychoactive medication

          -  Allergic to the drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>November 6, 2016</last_update_submitted>
  <last_update_submitted_qc>November 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Dose</keyword>
  <keyword>Bispectral index monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>safety</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

